These are mechanically computed values based on a residual income model. They are not a forecast of market prices or a recommendation of any investment action, and do not predict or guarantee future share prices. Historical values are computed retrospectively using current guidance-achievement statistics.
| Metric | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥901.0B | ¥862.0B | +4.5% |
| Operating Income | ¥180.8B | ¥197.8B | -8.6% |
| Profit Before Tax | ¥186.4B | ¥196.8B | -5.3% |
| Net Income | ¥105.8B | ¥135.4B | -21.8% |
| ROE | 2.4% | 3.0% | - |
Revenue increased while profit declined, as a decrease in gross margin, higher SG&A expenses, and an increase in the effective tax rate combined to weigh on quarterly net income attributable to owners of the parent. Revenue was ¥901.1B (¥862.0B in the same period last year, YoY+4.5%), Operating Income was ¥180.8B (¥197.8B, YoY-8.6%), and Profit Before Tax was ¥186.4B (¥196.8B, YoY-5.3%). Quarterly net income attributable to owners of the parent was ¥90.7B (¥118.4B, YoY-23.4%), while total quarterly profit including non-controlling interests was ¥105.8B (YoY-21.8%). Although revenue growth was driven by increases in Overseas, PatientSolution, and SiteSolution, a sharp decline in SiteSolution profit and lower revenue and profit in EvidenceSolution pressured profitability, while the increase in the effective tax rate to 43.2% (31.2% in the same period last year) amplified the decline in net income.
【Revenue】Revenue was ¥901.1B, an increase of +4.5% year on year. By segment, Overseas at ¥227.4B (+9.7%), PatientSolution at ¥147.5B (+9.9%), and SiteSolution at ¥141.6B (+9.0%) led overall performance with growth approaching double digits. In contrast, EvidenceSolution declined to ¥56.4B (-8.5%) and CareerSolution to ¥79.8B (-3.6%), while the core MedicalPlatform remained essentially flat at ¥243.8B (+0.9%).
【Profit and Loss】Operating Income was ¥180.8B (YoY-8.6%), and the operating margin was 20.1%, down 2.8pt from 22.9% in the same period last year. Gross margin was 49.3%, down 2.4pt from 51.7%, reflecting higher cost of sales and a mix shift toward less profitable segments. SG&A expenses increased to ¥278.1B (+6.7%), outpacing revenue growth of +4.5%, resulting in negative operating leverage. By segment, SiteSolution Operating Income plunged to ¥0.1B (-97.9%), while EvidenceSolution also declined sharply to ¥8.8B (-33.1%), making these the primary factors weighing on the company-wide margin. CareerSolution (profit margin 45.1%) and MedicalPlatform (36.4%) maintained high profitability, although both recorded lower profit, while PatientSolution improved to ¥7.5B (+66.3%). Profit Before Tax was ¥186.4B (-5.3%), supported by net financial income of ¥5.6B and equity-method income of ¥15.3B (¥10.4B in the same period last year). However, income taxes increased to ¥80.6B and the effective tax rate rose to 43.2% (31.2% in the same period last year), causing quarterly net income attributable to owners of the parent to decline by more than Operating Income, to ¥90.7B (-23.4%). Accordingly, the quarter was characterized by higher revenue but lower profit.
Only PatientSolution (Operating Income of ¥7.5B, +66.3%) secured an increase in profit among the seven segments, while all six remaining segments recorded lower profit. The largest change was in SiteSolution: despite higher revenue of ¥141.6B (+9.0%), Operating Income plunged to ¥0.1B (-97.9% from approximately ¥6.6B in the same period last year), with the profit margin falling to 0.1%, a level that contributed virtually no profit. EvidenceSolution also experienced both lower revenue and lower profit, with revenue of ¥56.4B (-8.5%) and Operating Income of ¥8.8B (-33.1%). The core MedicalPlatform, which generates approximately 49% of total company profit, remained essentially flat in revenue at ¥243.8B (+0.9%) but delivered stable Operating Income of ¥88.7B (-1.2%), maintaining a high profit margin of 36.4%. Overseas increased revenue to ¥227.4B (+9.7%) but recorded lower Operating Income of ¥46.1B (-4.9%), with the profit margin declining to 20.3% despite revenue growth. CareerSolution posted revenue of ¥79.8B (-3.6%) and Operating Income of ¥36.0B (-1.9%), maintaining a profit margin of 45.1% and recording a relatively modest decline in profit. Overall, among the segments with higher revenue (Overseas, PatientSolution, and SiteSolution), only PatientSolution achieved profit growth, highlighting the issue that revenue growth has not been accompanied by profit growth across the segment mix.
【Profitability】The operating margin was 20.1%, down 2.8pt from 22.9% in the same period last year, while the net margin declined to 10.1% on a basis attributable to owners of the parent (13.7% in the same period last year) and 11.7% on a consolidated quarterly profit basis (15.7% in the same period last year). ROE was 2.4%, and basic EPS declined to ¥13.60 from ¥17.44, a YoY decrease of -22.0%.【Cash Flow Quality】Cash and cash equivalents were ¥1621.7B, an increase of +3.8% from the beginning of the period, and depreciation and amortization was ¥43.5B. Trade receivables were ¥699.3B, a decrease of -6.2% from the beginning of the period, indicating a slight improvement in working capital.【Investment Efficiency】BPS was ¥605.97, slightly down from ¥608.98 at the beginning of the period, reflecting sluggish growth in equity accompanying the decline in net income. Total assets of ¥6348.0B and net assets of ¥4436.3B both remained essentially flat from the beginning of the period.【Financial Soundness】The Equity Ratio was 64.0%, unchanged from the beginning of the period. Interest-bearing debt, comprising short-term borrowings of ¥49.7B and long-term borrowings of ¥325.9B, totaled ¥375.6B against cash and cash equivalents of ¥1621.7B, indicating that the company continues to maintain a net cash position.
Although the cash flow statement has not been disclosed, movements in the balance sheet suggest that cash generation capacity has been maintained. Cash and cash equivalents increased by +¥6.0B (+3.8%), from ¥156.2B at the beginning of the period to ¥162.2B, while depreciation and amortization of ¥43.5B was recorded. Trade receivables were ¥699.3B, down -6.2% from ¥745.2B at the beginning of the period, while trade payables also declined by -3.2%, to ¥562.2B from ¥580.7B, indicating that changes in working capital had an offsetting effect. Long-term borrowings increased by +12.3%, to ¥325.9B from ¥289.8B at the beginning of the period, indicating an increase in long-term funding. Meanwhile, dividends from retained earnings totaling ¥170.9B were paid during the quarter, comprising ¥146.8B attributable to owners of the parent and ¥24.1B attributable to non-controlling interests. The increase in cash and cash equivalents therefore reflects the result after absorbing these cash outflows. Given the level of net cash—cash of ¥1621.7B against interest-bearing debt of ¥375.6B—the company is expected to retain substantial capacity to respond to dividends and working capital fluctuations.
While quarterly profit including non-controlling interests was ¥105.8B, total quarterly comprehensive income was ¥140.8B, exceeding it by ¥35.0B. This difference comprised total other comprehensive income, net of tax, of ¥34.96B, specifically foreign currency translation adjustments for foreign operations of +¥22.6B, the share of OCI of equity-method affiliates of +¥11.0B, and fair value remeasurements of +¥1.35B. On a basis attributable to owners of the parent, comprehensive income was ¥123.7B versus quarterly net income of ¥90.7B, a difference of ¥33.0B, with foreign exchange-related factors such as foreign currency translation adjustments making a significant contribution. On the profit and loss side, equity-method income of ¥15.3B (¥10.4B in the same period last year) provided recurring support, while net financial income improved to ¥5.6B from a net financial expense of ¥0.9B in the same period last year. Meanwhile, income taxes were ¥80.6B, and the effective tax rate increased to 43.2% from 31.2% in the same period last year, with the higher tax burden being the primary factor causing the decline in net income attributable to owners of the parent to exceed the decline in Operating Income. No items equivalent to extraordinary gains or losses were explicitly disclosed, and fluctuations in profit for the period are therefore understood to have been driven primarily by recurring factors, namely changes in segment mix and the tax burden.
Against the full-year company forecasts (Revenue of ¥400.0B, Operating Income of ¥80.0B, Net Income of ¥56.0B, Net Income Attributable to Owners of the Parent of ¥53.0B, and EPS of ¥78.29), Q1 progress was 22.5% for Revenue and 22.6% for Operating Income, slightly below the simple one-quarter benchmark of 25%. Progress was weaker for net income: 18.9% on a consolidated quarterly profit basis, 17.1% on a net income attributable to owners of the parent basis, and 17.4% on an EPS basis. The primary reason progress for net income-related metrics substantially lagged Revenue and Operating Income is believed to be the elevated effective tax rate of 43.2%. As of the current quarter, no revisions have been made to the earnings forecast or dividend forecast.
The dividend forecast for the fiscal year ending March 2027 is currently undecided, with the company indicating that it will determine the dividend after considering future funding requirements and cash flow conditions. During the quarter, dividends from retained earnings totaling ¥170.9B were paid, comprising ¥146.8B attributable to owners of the parent and ¥24.1B attributable to non-controlling interests, approximately the same level as the ¥170.9B total in the same period last year. Share repurchases were minimal (¥0.0B), declining significantly from ¥8.8B in the same period last year. Because the dividend forecast has not been determined, the Payout Ratio and Total Return Ratio cannot be calculated. However, the net cash position—cash and cash equivalents of ¥1621.7B and interest-bearing debt of ¥375.6B—will remain a monitoring point in terms of future sources of shareholder returns.
Segment Mix Change Risk: SiteSolution Operating Income plunged to ¥0.1B (前年比-97.9%), while EvidenceSolution also declined to ¥8.8B (-33.1%). Combined revenue from the two segments was ¥198.0B (22.0% of total revenue), and deteriorating profitability has weighed on the company-wide operating margin of 20.1%.
Increased Tax Burden Risk: The effective tax rate was 43.2%, up 12.0pt from 31.2% in the same period last year. While Profit Before Tax declined by only -5.3%, net income attributable to owners of the parent fell substantially by -23.4%, meaning that tax burden trends could affect future earnings progress.
Goodwill and Intangible Asset-Related Risk: Goodwill of ¥1257.1B and intangible fixed assets of ¥993.7B totaled ¥2250.8B, representing 35.5% of total assets of ¥6348.0B. From the end of the previous fiscal year, goodwill increased by +1.3% and intangible fixed assets by +0.2%, remaining essentially flat with no significant increase. Nevertheless, their high weighting in the asset structure remains a point requiring continued monitoring.
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 20.1% | 8.1% (2.3%–15.9%) | +12.0pt |
| Net Margin | 11.7% | 5.9% (1.6%–10.7%) | +5.9pt |
Both the operating margin and net margin significantly exceed the industry median, placing the company’s profitability among the higher levels within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (Year on Year) | 4.5% | 9.3% (0.4%–16.9%) | -4.8pt |
The revenue growth rate is below the industry median, indicating that the pace of growth is relatively moderate compared with the high level of profitability.
※Source: Compiled by the Company
Although profitability remains high within the industry, it has been trending downward. The operating margin declined by 2.8pt from 22.9% in the same period last year to 20.1%, while gross margin also declined by 2.4pt from 51.7% to 49.3%. SG&A expense growth (+6.7%) exceeded revenue growth (+4.5%), resulting in negative operating leverage.
Progress against the full-year forecast was in the 22% range for Revenue and Operating Income, while net income-related metrics remained in the 17–19% range. The increase in the effective tax rate to 43.2% from 31.2% in the same period last year is the cause, creating a structure in which tax burden trends will determine progress toward the full-year forecast.
Performance varied significantly across segments. Deteriorating profitability at SiteSolution (Operating Income -97.9%) and EvidenceSolution (-33.1%) weighed on the company-wide margin, while PatientSolution (+66.3%) continued to improve. CareerSolution and MedicalPlatform maintained high profit margins (45.1% and 36.4%, respectively), making changes in the segment mix a key determinant of earnings quality.
This is a mechanically calculated reference range based solely on publicly available data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear (bearish) | ¥665 |
| base (base case) | ¥683 |
| bull (bullish) | ¥705 |
| Calculation Assumption | Value |
|---|---|
| Book Value Per Share (BPS) | ¥606 |
| Adjusted Forecast EPS | ¥82.1 |
| Cost of Equity r | 9.27% (10-year government bond 2.77% + equity risk premium 6.00% + size premium 0.50%) |
| Persistence Parameter for Residual Income ω / Explicit Forecast | 0.62 / 5 years |
| Assumed Payout Ratio | 30.0% |
| Forecast EPS Confidence Adjustment | ×1.049 (based on the historical guidance achievement rate for peers in the same industry) |
| implied PBR / PER |
Sensitivity: ¥664–¥703 at ±1% for the cost of equity, and ¥681–¥686 at ±0.1 for ω.
Notes:
(Calculation model: residual income model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee the future share price)
This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
| 1.13x / 8.3x |